0001850767 false 0001850767 2023-06-05 2023-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 5, 2023

 

 

AccuStem Sciences Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware   000-56257   87-3774438

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

5 Penn Plaza, 19th Floor, #1954

New York, NY

  10001
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 00 44 2074952379

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

 

On June 5, 2023, Jeff Fensterer, the Chief Operating Officer of AccuStem Sciences Inc. (the “Company”) resigned his position with the Company for personal reasons, effective as of June 16, 2023. Jeff Fensterer will be moving to a consulting position with the Company.

 

-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ACCUSTEM SCIENCES INC.
   
Date: June 9, 2023 By: /s/ Wendy Blosser
      Wendy Blosser
    Chief Executive Officer

 

-3-

 

 

Accustem Sciences (QB) (USOTC:ACUT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Accustem Sciences (QB) Charts.
Accustem Sciences (QB) (USOTC:ACUT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Accustem Sciences (QB) Charts.